Cellbricks Therapeutics

Cellbricks Therapeutics is a pioneering biotech company aiming to address the critical unmet need for tissue restoration by developing biofabricated human tissue therapeutics. Its core technology integrates a proprietary light-based biofabrication system with AI-driven tissue engineering software to produce scalable and precise living tissue implants. The company is in the pre-clinical stage, backed by institutional investors and strategic hires like former BioNTech CFO Michael Kring, and is advancing its platform towards clinical applications for soft tissue defects and organ dysfunction.

Integrated platform combining proprietary light-based biofabrication (hardware/process) with AI-driven tissue engineering software for the design and scalable manufacturing of functional, immune-compatible human tissue therapeutics.

Cellbricks operates in the competitive tissue engineering and regenerative medicine space, competing with other bioprinting companies (e.g., 3D Systems, CELLINK/BICO, Prellis Biologics) and cell therapy firms developing scaffold-based implants. Its key differentiator is the integration of a proprietary light-based fabrication process with AI for design and process control, aiming for superior scalability and precision.